What Are the Stages of MS? From Prodrome to Advanced Disease

Multiple sclerosis follows a course that neurologists divide into recognized phenotypes rather than neat, numbered stages. Most people are diagnosed with relapsing-remitting MS, marked by flare-ups of neurological symptoms followed by partial or full recovery. Over years or decades, a majority of those individuals transition into a progressive phase where disability accumulates steadily, with or without superimposed relapses. A smaller group never experiences the relapsing pattern at all, instead accruing disability from the outset. Understanding these phases matters because treatment options, prognosis, and day-to-day management shift meaningfully at each point.

How the Disease Is Classified Today

The modern classification of MS was established in 1996 and revised in 2013. It recognizes four main phenotypes: clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), and primary progressive MS (PPMS). The 2013 revision added an important qualifier on top of each phenotype: disease activity, meaning whether new brain lesions are forming on MRI or clinical relapses are occurring.¹ The framework also distinguishes between active disease and progression, so a person with RRMS can be described as “active” or “not active,” and someone with SPMS can be classified as “active with progression” or “not active with progression.”²

These categories are clinical descriptions, not biological certainties. Researchers acknowledge that clear imaging, immunologic, or pathologic boundaries separating one phenotype from another have not been firmly established.³ In practice, this means that the “stage” you are told you have is based largely on your clinical history and MRI patterns, with some judgment calls involved, especially when it comes to the murky transition between relapsing and progressive disease.

Before the First Attack: The Prodromal Phase

MS may not begin with the first dramatic symptom a person notices. Research from primary-care records shows that various clinical disturbances precede an MS diagnosis by several years, supporting a prodromal phase of the disease.⁴ These early signs can include fatigue, mood changes, pain, and bladder problems that seem unrelated at the time. None of these are specific to MS on their own, which is why the prodromal phase typically goes unrecognized until someone looks backward from a confirmed diagnosis. The hope is that recognizing these early patterns could eventually lead to earlier identification and treatment, but at present the prodrome is more of a retrospective observation than a practical clinical tool.

Clinically Isolated Syndrome

CIS is the first clinical episode that looks like MS but has not yet been confirmed as such. A person might experience optic neuritis (inflammation of the optic nerve causing vision loss), numbness or tingling in a limb, or balance problems lasting at least 24 hours. At this point, the question is whether it will happen again. If MRI and spinal fluid findings meet certain criteria, a diagnosis of MS can sometimes be made even after a single episode. The current McDonald criteria, last updated in 2017, allow MS to be diagnosed at the CIS stage if MRI shows lesions spread across different parts of the central nervous system and if cerebrospinal fluid contains oligoclonal bands, which are markers of immune activity in the brain and spinal cord.⁵ Not everyone with CIS goes on to develop MS, but those whose MRI already shows characteristic lesions are at higher risk of doing so.

Relapsing-Remitting MS

About 85% of people with MS are initially diagnosed with the relapsing-remitting form. RRMS is defined by episodes of new or worsening neurological symptoms (relapses) followed by periods of partial or full recovery (remissions). Relapses reflect bursts of acute inflammation in the brain or spinal cord. Different areas of the central nervous system tend to be affected with each relapse, which is why symptoms can vary so much from one episode to the next: one flare might cause visual problems while the next causes weakness in a leg.⁶

Remission does not mean the disease has stopped. During quiet periods, the resolution of inflammation is the main driver of clinical improvement, and the immune system may even play a helpful role by promoting repair of damaged nerve insulation.⁷ But recovery to the pre-relapse baseline is often incomplete, meaning that small amounts of disability can accumulate even during what appears to be a “stable” phase.⁸ This is one of the reasons why relying solely on how you feel between attacks can be misleading about what is happening in the brain.

The Transition to Secondary Progressive MS

SPMS is what clinicians call it when a person who started with relapsing-remitting disease shifts into a phase of steady disability accumulation, with or without ongoing relapses. This transition is one of the most feared aspects of MS, and it is also one of the hardest to pin down. No single test or scan reliably marks the moment someone has crossed from RRMS into SPMS. Clear clinical, imaging, immunologic, or pathologic criteria marking this transition have not yet been established.⁹ In practice, the diagnosis is often made retrospectively, once a pattern of worsening over months or years becomes undeniable.

Researchers are working on indicators that could catch the shift earlier. Cognitive impairment, especially in working memory, information processing speed, and verbal fluency, may serve as a signal. MRI findings such as slowly expanding lesions and thinning of retinal layers on specialized eye scans also show promise. Certain proteins in the blood, particularly glial fibrillary acidic protein and chitinase-3-like protein 1, may be better at identifying the conversion to progressive disease than the more widely studied neurofilament light chain.¹⁰ None of these markers are used routinely yet, but they represent a direction of travel in research that could eventually make the SPMS diagnosis more timely and objective.

Primary Progressive MS

About 10 to 15% of people with MS skip the relapsing-remitting phase entirely and begin with steady worsening from disease onset. This is primary progressive MS. People with PPMS often present with gradually increasing difficulty walking, often due to stiffness and weakness in the legs, without the distinct attacks and recoveries that characterize RRMS. PPMS tends to be diagnosed later in life and has a more even sex ratio compared to the female-predominant relapsing forms.

The underlying biology of PPMS overlaps with what drives progression in SPMS, involving widespread nerve fiber damage, brain and spinal cord shrinkage, and low-grade inflammation that does not produce the dramatic flares seen in relapsing disease. PPMS has historically been harder to treat because many therapies designed to suppress the acute inflammation of relapses are less effective against the smoldering processes that drive progressive worsening. The approval of certain therapies for active PPMS in recent years has narrowed this treatment gap somewhat, but options remain more limited than for relapsing forms.

Disability Worsening Without Relapses

An increasingly important concept is that disability can accumulate independently of relapses, even in people who appear to have “relapsing” disease. This phenomenon, referred to as progression independent of relapse activity, or PIRA, challenges the traditional view that the relapsing-remitting phase is benign between attacks. Research shows that silent, ongoing nerve damage contributes to disability creep that cannot be explained by the relapses a person experiences.¹¹ The PIRA concept underscores why monitoring MS only by counting relapses misses part of the picture. It also helps explain why some people with few relapses still develop significant disability over time.

Blood and Imaging Biomarkers for Tracking Progression

Doctors and researchers want objective ways to measure what MS is doing between clinic visits. The most promising blood marker right now is neurofilament light chain (NfL), a protein released when nerve fibers are damaged. In people with progressive MS, blood levels of NfL tend to be roughly 50% higher than in those with relapsing disease, even after adjusting for age.¹² Higher NfL levels at a given time point correlate with worse scores on disability scales, greater brain volume loss, and poorer cognitive function. One study tracking patients over 12 years found that those whose disability worsened showed a steeper rise in NfL over time compared to those who remained stable.¹³

The challenge with NfL is that active inflammation also drives it up, making it difficult to tell whether a high reading reflects smoldering progression or a recent inflammatory flare.¹⁴ Researchers are still working out how to separate these two signals in clinical practice.

On the imaging side, brain and spinal cord shrinkage measured by MRI has become an important marker. The destructive aspects of the disease develop early, and tissue loss correlates with clinical impairment more closely than the bright spots (lesions) that neurologists traditionally count on MRI scans.¹⁵ Spinal cord atrophy is particularly telling: lesions and tissue loss in the spinal cord are already present in the relapsing phase but become more pronounced in progressive disease, and both contribute to the clinical picture.¹⁶ In one study, the rate of upper spinal cord atrophy was the strongest MRI predictor of future conversion from RRMS to SPMS, with each 1% faster annual atrophy rate associated with a 53% shorter time to that conversion.¹⁷

Measuring Disability Along the Way

The most widely used yardstick for MS disability is the Expanded Disability Status Scale, or EDSS. It runs from 0 (normal neurological exam) to 10 (death due to MS) and is based on a neurologist’s evaluation of various functional systems including vision, strength, coordination, sensation, bladder function, and cognition.¹⁸ Key milestones along the scale include EDSS 4 (limited walking ability but can walk about 500 meters without rest), EDSS 6 (needs a cane or other support to walk about 100 meters), and EDSS 7 (essentially restricted to a wheelchair). The time a person spends at any given EDSS level varies widely, and the specific functional domains affected can predict how quickly someone is likely to move to the next level.¹⁹

The EDSS is far from perfect. It is heavily weighted toward walking ability, which means that someone whose MS primarily affects their hands, vision, or thinking can have a deceptively low score. It is also not very sensitive to small changes, especially in the middle range. Despite these limitations, it remains the standard in both clinical practice and research trials, and improvements on the EDSS have been shown to correlate with gains in quality of life.²⁰

How Age at Onset Shapes the Course

The age at which MS begins has a strong influence on how the disease unfolds. Childhood-onset MS (before age 18) almost always starts as relapsing-remitting disease, with about 98% following that pattern compared to 84% in adult-onset cases. Children take roughly ten years longer to reach the secondary progressive phase and irreversible disability milestones, but they reach those milestones at a younger age than people diagnosed as adults.²¹ In other words, the disease seems to move more slowly clock-year by clock-year in children, but the earlier start means they accumulate significant disability during what should be their most productive decades.

At the other end of the spectrum, late-onset MS (diagnosed after age 50) follows a distinctly different trajectory. A much larger fraction of late-onset cases are primary progressive, with one Swedish study reporting that about 25% of late-onset patients had PPMS compared to roughly 5% of typical adult-onset patients.²² Late-onset MS is associated with faster progression to disability milestones, with the risk of reaching significant disability roughly two and a half times higher than in typical adult-onset disease.²³ Initial motor or cerebellar symptoms and a higher proportion of men are also more common in this group.²⁴ These differences likely reflect both the biology of aging nervous systems and the greater burden of neurodegeneration relative to inflammation in older individuals.

Data on disability worsening that is independent of relapses (PIRA) shows a graded effect across age groups. When PIRA occurs in late-onset MS, the disability trajectory is notably steeper than in typical adult-onset or childhood-onset disease.²⁵ This reinforces the general observation that aging amplifies the progressive component of MS.

Why Early Treatment Matters for Long-Term Stage Progression

One of the strongest arguments for aggressive early treatment comes from studies looking at whether starting disease-modifying therapy sooner changes the long-term odds of transitioning to SPMS. A large observational study found that people who started treatment within five years of MS onset were significantly less likely to convert to secondary progressive disease compared to matched patients who started the same therapies later. At the 17-year mark, about 29% of early starters had converted to SPMS, compared to 47% of later starters.²⁶ The benefit also held for patients who escalated from initial therapies to more potent ones: early escalation was associated with lower conversion rates than later escalation.²⁷

Separately, longitudinal data show that exposure to disease-modifying therapy in general is associated with a roughly 30% lower risk of developing secondary progressive disease.²⁸ These findings have shifted clinical thinking toward “hit hard, hit early” strategies, though the evidence is observational and decisions must still be individualized.

Modifiable Factors That Influence Progression

Beyond medication, a few lifestyle and environmental factors have evidence linking them to how fast MS worsens. Smoking stands out: smokers with MS face a higher risk of disability progression, with one meta-analysis estimating roughly a 55% increased hazard.²⁹ Vitamin D is another factor that comes up repeatedly. Lower blood vitamin D levels are associated with higher disability scores across multiple studies, though the relationship is modest in size and the question of whether supplementation actually slows progression (as opposed to just being a marker of disease activity) is still debated.³⁰ There is also some evidence that sun exposure independently of vitamin D may influence disease activity and disability.³¹

Cognitive Changes Across Stages

Thinking and memory problems do not get as much attention as mobility difficulties, but they affect a large proportion of people with MS at every stage. A long-term follow-up study identified two distinct cognitive trajectories: about half the patients maintained stable performance on a processing speed test over time, while the other half showed a pattern of worsening.³² The existence of these two tracks is meaningful because it shows cognitive decline is not inevitable, even though it is common. It also highlights that cognitive outcomes are not captured well by the EDSS, which focuses heavily on physical function. For many people with MS, the impact on concentration, multitasking, and word-finding has a bigger effect on daily life than the degree of limb weakness the EDSS measures.

Advanced MS and Its Challenges

In the later stages of progressive MS, disability extends well beyond difficulty walking. Respiratory dysfunction becomes increasingly common as MS advances. In one study of people with advanced disease, about 61% reported at least one respiratory symptom including weak cough, difficulty breathing, or trouble clearing airway secretions. Among those with the highest levels of disability (EDSS 9 or above, meaning essentially bedbound), respiratory symptoms were reported in 94% and respiratory interventions in 76%.³³

Rehabilitation at this stage shifts focus toward preventing complications and managing specific problems such as spasticity, pain, speech and swallowing difficulties, and bladder, bowel, and sexual dysfunction. The rehabilitation team works with patients and family members on both physical and psychosocial issues.³⁴ Palliative care, still underused in MS, has been shown to improve symptoms like pain, nausea, and sleep disorders in people with advanced disease when compared to conventional management alone.³⁵ Palliative care in this context is not about end of life; it is about quality of life and symptom control alongside ongoing disease management.

The Gut Microbiome and Progressive Disease

An emerging and somewhat unexpected line of research involves the gut microbiome. Studies comparing the gut bacteria of people with progressive MS to those with relapsing disease and healthy controls have found patterns unique to progressive MS. Both forms of MS share certain microbial shifts, including increases in some bacterial species and decreases in others. But progressive MS specifically shows elevated levels of certain Enterobacteriaceae and reduced levels of Blautia species, changes not seen in relapsing patients.³⁶ Whether these differences drive progression, result from it, or simply travel alongside it is not yet clear. But the finding that different stages of MS carry distinct microbial signatures opens a possible window into understanding and eventually influencing the disease process through routes that have nothing to do with traditional immunosuppression.